{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:53:25Z","timestamp":1784426005961,"version":"3.55.0"},"reference-count":157,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009946","name":"Allergopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017255","name":"Allergy Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jaip.2020.04.071","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T22:38:45Z","timestamp":1589582325000},"page":"2920-2936.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report"],"prefix":"10.1016","volume":"8","author":[{"given":"Mois\u00e9s A.","family":"Calderon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Waserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Demoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance H.","family":"Katelaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Christian","family":"Virchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"DuBuske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.04.071_bib1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/all.13208","article-title":"Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis","volume":"72","author":"Dhami","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/all.13201","article-title":"Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis","volume":"72","author":"Dhami","year":"2017","journal-title":"Allergy"},{"issue":"Suppl 82","key":"10.1016\/j.jaip.2020.04.071_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1398-9995.2006.01219_1.x","article-title":"Standards for practical allergen-specific immunotherapy","volume":"61","author":"Alvarez-Cuesta","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1939-4551-7-6","article-title":"Sublingual immunotherapy: World Allergy Organization position paper 2013 update","volume":"7","author":"Canonica","year":"2014","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2020.04.071_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","article-title":"Allergen immunotherapy: a practice parameter third update","volume":"127","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s40629-014-0032-2","article-title":"Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases","volume":"23","author":"Pfaar","year":"2014","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2020.04.071_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anl.2013.06.003","article-title":"Guiding principles of subcutaneous immunotherapy for allergic rhinitis in Japan","volume":"41","author":"Okamoto","year":"2014","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.jaip.2020.04.071_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anl.2015.08.015","article-title":"Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients","volume":"43","author":"Masuyama","year":"2016","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.jaip.2020.04.071_bib9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5694\/j.1326-5377.1997.tb138878.x","article-title":"Specific allergen immunotherapy for asthma. A position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy","volume":"167","year":"1997","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaip.2020.04.071_bib10","first-page":"47","article-title":"Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI)","volume":"2","author":"Leith","year":"2006","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/all.13317","article-title":"EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis","volume":"73","author":"Roberts","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40413-015-0078-8","article-title":"Allergen immunotherapy on the way to product-based evaluation\u2014a WAO statement","volume":"8","author":"Bachert","year":"2015","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2020.04.071_bib13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jaip.2018.08.032","article-title":"Allergen extracts for in\u00a0vivo diagnosis and treatment of allergy: is there a future?","volume":"6","author":"Valenta","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib14","series-title":"Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP\/EWP\/18504. Committee for Medicinal Products for Human Use","year":"2008"},{"key":"10.1016\/j.jaip.2020.04.071_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2010.11.034","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents","volume":"127","author":"Blaiss","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib16","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaci.2012.08.032","article-title":"Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE","volume":"130","author":"Cox","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib17","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaci.2013.03.019","article-title":"Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults","volume":"131","author":"Creticos","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2006.05.003","article-title":"Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis","volume":"118","author":"Dahl","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jaci.2007.07.046","article-title":"Optimal\u00a0dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis","volume":"120","author":"Didier","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2016.06.044","article-title":"Efficacy of house dust mite SLIT-tablet in North American adolescents and adults in a randomized, placebo-controlled trial","volume":"138","author":"Nolte","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.anai.2013.03.013","article-title":"Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults","volume":"110","author":"Nolte","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jaip.2018.11.044","article-title":"Long-term efficacy and dose-finding trial of Japanese cedar pollen sublingual immunotherapy tablet","volume":"7","author":"Gotoh","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib25","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/all.13544","article-title":"Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children","volume":"73","author":"Masuyama","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/pai.12984","article-title":"Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: a randomized trial in a pediatric population","volume":"30","author":"Okamoto","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/all.12996","article-title":"House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis","volume":"72","author":"Okamoto","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib28","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaci.2016.09.043","article-title":"Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis","volume":"139","author":"Okubo","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaci.2010.09.017","article-title":"The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article","volume":"127","author":"Bousquet","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40629-018-0058-y","article-title":"Positive and negative AIT trials: what makes the difference?","volume":"27","author":"Gerth van Wijk","year":"2018","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaip.2020.04.071_bib31","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jaci.2013.09.004","article-title":"An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies","volume":"132","author":"Calderon","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/ACI.0000000000000104","article-title":"Update on house dust mite immunotherapy: are more studies needed?","volume":"14","author":"Nelson","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.23822\/EurAnnACI.1764-1489.100","article-title":"Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality","volume":"51","author":"Domdey","year":"2019","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/ACI.0b013e32832b4651","article-title":"Why do doctors and patients not follow guidelines?","volume":"9","author":"Baiardini","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib35","first-page":"15","article-title":"Characteristics of effective clinical guidelines for general practice","volume":"53","author":"Burgers","year":"2003","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib36","series-title":"Allergen immunotherapy pocket guide","author":"Kim","year":"2016"},{"key":"10.1016\/j.jaip.2020.04.071_bib37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1398-9995.2010.02474.x","article-title":"GA(2) LEN\/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma","volume":"65","author":"Zuberbier","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib38","author":"Canonica"},{"key":"10.1016\/j.jaip.2020.04.071_bib39","unstructured":"American College of Allergy, Asthma, and Immunology; American Academy of Allergy, Asthma, and Immunology. Sublingual Immunotherapy Digital Pocket Guidelines. Available from: https:\/\/www.guidelinecentral.com\/allergymembers\/. Accessed June 16, 2020."},{"key":"10.1016\/j.jaip.2020.04.071_bib40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaci.2008.10.044","article-title":"Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy","volume":"123","author":"Bufe","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaci.2008.10.009","article-title":"Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis","volume":"123","author":"Wahn","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib42","doi-asserted-by":"crossref","first-page":"50","DOI":"10.24953\/turkjped.2018.01.007","article-title":"Knowledge levels related to allergen specific immunotherapy and perspectives of parents whose children were diagnosed with asthma and\/or allergic rhinitis in Turkey","author":"I\u015f\u0131k","year":"2018","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.jaip.2020.04.071_bib43","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3928\/00904481-20140723-09","article-title":"New developments in the treatment of pediatric allergic rhinitis and conjunctivitis","volume":"43","author":"Lierl","year":"2014","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.jaip.2020.04.071_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anai.2016.02.001","article-title":"Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: national surveillance study on allergen immunotherapy (2008-2013)","volume":"116","author":"Epstein","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib45","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jaip.2019.01.058","article-title":"AAAAI\/ACAAI subcutaneous immunotherapy (SCIT) surveillance study (2013-2017): fatalities, infections, delayed reactions and use of epinephrine auto-injectors","volume":"7","author":"Epstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib48","author":"Leonard"},{"key":"10.1016\/j.jaip.2020.04.071_bib49","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/cea.12331","article-title":"A\u00a0comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis","volume":"44","author":"Calderon","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib50","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jaip.2019.01.015","article-title":"Validation of patient-reported outcomes for clinical trials in allergic rhinitis: a systematic review","volume":"7","author":"Calderon","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2006.01312.x","article-title":"Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib52","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.anai.2012.08.013","article-title":"Assessment of specific immunotherapy efficacy using a novel placebo score-based method","volume":"109","author":"Frew","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1398-9995.1998.tb04082.x","article-title":"Immunotherapy as an effective tool in allergy treatment","volume":"53","author":"Malling","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib54","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaci.2016.04.061","article-title":"Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses","volume":"138","author":"Durham","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib55","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaci.2011.03.049","article-title":"Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses","volume":"128","author":"Matricardi","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1741-7015-12-71","article-title":"A\u00a0meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis","volume":"12","author":"Devillier","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.jaip.2020.04.071_bib57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11882-017-0687-0","article-title":"Allergen immunotherapy clinical trial outcomes and design: working toward harmonization of methods and principles","volume":"17","author":"Nelson","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2020.04.071_bib58","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/all.13925","article-title":"Determination of the minimally important difference in a nasal symptom score in house dust mite allergy","volume":"74","author":"Devillier","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.0954-7894.2002.01327.x","article-title":"Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial","volume":"32","author":"Lima","year":"2002","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2018.09.039","article-title":"Nasal allergen-neutralizing IgG4 antibodies block IgE-mediated responses: novel biomarker of subcutaneous grass pollen immunotherapy","volume":"143","author":"Shamji","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1398-9995.2011.02759.x","article-title":"Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients","volume":"67","author":"Howarth","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib62","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1398-9995.2011.02590.x","article-title":"How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement","volume":"66","author":"Bousquet","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib63","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5114\/ada.2018.77614","article-title":"Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials","volume":"35","author":"Abramowicz","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaip.2020.04.071_bib64","doi-asserted-by":"crossref","first-page":"238","DOI":"10.5414\/ALX01534","article-title":"Clinical efficacy and immunological response in children is similar to that of adults after the first treatment season with SQ-standardized grass allergy immunotherapy tablet in two randomized trials","volume":"36","author":"Bufe","year":"2013","journal-title":"Allergologie"},{"key":"10.1016\/j.jaip.2020.04.071_bib65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib66","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2017.06.014","article-title":"Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy","volume":"141","author":"Valovirta","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib68","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jaci.2017.09.051","article-title":"Effect of grass sublingual tablet immunotherapy is similar in children and adults: a Bayesian approach to design pediatric sublingual immunotherapy trials","volume":"141","author":"Kaur","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib69","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.anai.2011.05.020","article-title":"Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI\/AAAAI surveillance study of subcutaneous immunotherapy: year 2","volume":"107","author":"Epstein","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib70","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/all.13066","article-title":"European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment","volume":"72","author":"Calderon","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib71","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jaci.2004.02.006","article-title":"Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001","volume":"113","author":"Bernstein","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib72","series-title":"Full prescribing information","year":"2014"},{"key":"10.1016\/j.jaip.2020.04.071_bib73","series-title":"Full prescribing information","year":"2014"},{"key":"10.1016\/j.jaip.2020.04.071_bib74","series-title":"Full prescribing information. Antony, France","year":"2014"},{"key":"10.1016\/j.jaip.2020.04.071_bib75","series-title":"Full prescribing information. H\u00f8rsholm","year":"2017"},{"key":"10.1016\/j.jaip.2020.04.071_bib76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.anai.2011.02.007","article-title":"Systemic reactions associated with subcutaneous allergen immunotherapy: timing and risk assessment","volume":"106","author":"DaVeiga","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib77","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2500\/ajra.2012.26.3811","article-title":"The risk and management of anaphylaxis in the setting of immunotherapy","volume":"26","author":"Lieberman","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib78","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1081-1206(10)62195-3","article-title":"Systemic reactions and fatalities associated with allergen immunotherapy","volume":"87","author":"Lockey","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib79","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2016.05.014","article-title":"Coseasonal initiation of allergen immunotherapy: a systematic review","volume":"4","author":"Creticos","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.anai.2014.04.018","article-title":"Safety and tolerability of a short ragweed sublingual immunotherapy tablet","volume":"113","author":"Nolte","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib81","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2011.02761.x","article-title":"Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile","volume":"67","author":"Calderon","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib82","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1517\/14740338.2015.1017468","article-title":"Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review","volume":"14","author":"Didier","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2020.04.071_bib83","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jaci.2013.01.049","article-title":"Update on allergy immunotherapy: American Academy of Allergy,\u00a0Asthma & Immunology\/European Academy of Allergy and Clinical Immunology\/PRACTALL consensus report","volume":"131","author":"Burks","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib84","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/all.12560","article-title":"Safety of sublingual immunotherapy timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma","volume":"70","author":"Maloney","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib85","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1001\/jama.2016.3964","article-title":"Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial","volume":"315","author":"Virchow","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2020.04.071_bib86","first-page":"409","article-title":"Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts","volume":"73","author":"Portnoy","year":"1994","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib87","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0091-6749(96)70186-0","article-title":"Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study","volume":"97","author":"Nielsen","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib88","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1081-1206(10)63556-9","article-title":"Effect of pretreatment with fexofenadine on the safety of immunotherapy in patients with allergic rhinitis","volume":"96","author":"Ohashi","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib89","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaip.2014.01.004","article-title":"AAAAI\/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions","volume":"2","author":"Epstein","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib90","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib91","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaci.2009.11.022","article-title":"Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma","volume":"125","author":"Massanari","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib92","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/02770900902785729","article-title":"Mechanisms of sublingual immunotherapy","volume":"46","author":"Scadding","year":"2009","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2020.04.071_bib93","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/00325481.2017.1302306","article-title":"A\u00a0practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice","volume":"129","author":"Bernstein","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jaip.2020.04.071_bib94","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2013.03.039","article-title":"Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language","volume":"132","author":"Passalacqua","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib95","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.anai.2016.01.015","article-title":"Local and systemic reactions to subcutaneous allergen immunotherapy: ten years' experience in a pediatric clinic","volume":"116","author":"Nacaroglu","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib96","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.anai.2014.08.004","article-title":"Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis","volume":"113","author":"Lucendo","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib97","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11882-018-0798-2","article-title":"What is the relationship between eosinophilic esophagitis (EoE) and aeroallergens? Implications for allergen immunotherapy","volume":"18","author":"Egan","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2020.04.071_bib98","first-page":"363","article-title":"Straumann, Induction of eosinophilic esophagitis by sublingual pollen immunotherapy","volume":"7","author":"Miehlke","year":"2013","journal-title":"Case Reports Case Rep Gastroenterol"},{"key":"10.1016\/j.jaip.2020.04.071_bib99","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/all.13266","article-title":"Challenges in the implementation of EAACI guidelines on allergen immunotherapy: a global perspective on the regulation of allergen products","volume":"73","author":"Bonertz","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib100","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jaci.2019.01.024","article-title":"Understanding differences in allergen immunotherapy products and practices in North America and Europe","volume":"143","author":"Mahler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib102","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2014.10.045","article-title":"Environmental exposure chambers in allergen immunotherapy trials: current status and clinical validation needs","volume":"135","author":"Rosner-Friese","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib103","series-title":"EMA\/PDCO standard paediatric investigation plan for allergen products for specific immunotherapy (EMA\/PDCO\/737605\/2009)","year":"2015"},{"key":"10.1016\/j.jaip.2020.04.071_bib104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12948-017-0070-7","article-title":"Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence","volume":"15","author":"Martignago","year":"2017","journal-title":"Clin Mol Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/pai.12661","article-title":"Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis","volume":"28","author":"Kristiansen","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib106","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/1744666X.2017.1398082","article-title":"Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis","volume":"13","author":"Devillier","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib107","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/all.13598","article-title":"Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma","volume":"74","author":"Wahn","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib108","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/all.13213","article-title":"Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis","volume":"73","author":"Zielen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib109","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/all.13104","article-title":"Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review","volume":"72","author":"Di Bona","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.anai.2015.12.006","article-title":"Dog allergen immunotherapy: past, present, and future","volume":"116","author":"Smith","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib111","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/cea.13242","article-title":"Efficacy and safety of allergen immunotherapy in patients with allergy to molds: a systematic review","volume":"48","author":"Di Bona","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib112","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jaci.2004.08.049","article-title":"Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract","volume":"114","author":"Nanda","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib113","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40521-018-0176-2","article-title":"Duration of allergen immunotherapy for long-term efficacy in allergic rhinoconjunctivitis","volume":"5","author":"Penagos","year":"2018","journal-title":"Curr Treat Options Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib114","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1398-9995.2011.02669.x","article-title":"European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy","volume":"66","author":"Calderon","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib115","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.anai.2017.12.013","article-title":"Current and future challenges of subcutaneous and sublingual allergy immunotherapy for allergists in the United States","volume":"121","author":"Nelson","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib116","first-page":"CD001936","article-title":"Allergen injection immunotherapy for seasonal allergic rhinitis","author":"Calderon","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2020.04.071_bib117","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaci.2013.02.013","article-title":"Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison","volume":"131","author":"Dretzke","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2500\/ar.2015.6.0111","article-title":"Practical recommendations for mixing allergy immunotherapy extracts","volume":"6","author":"Daigle","year":"2015","journal-title":"Allergy Rhinol (Providence)"},{"key":"10.1016\/j.jaip.2020.04.071_bib119","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.anai.2011.07.001","article-title":"Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units","volume":"107","author":"Larenas-Linnemann","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/1744666X.2016.1237288","article-title":"300 IR HDM\u00a0tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis","volume":"12","author":"Demoly","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000444016","article-title":"Fractionation of source materials leads to high reproducibility of SQ HDM SLIT-tablets","volume":"169","author":"Henmar","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib122","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaci.2009.06.006","article-title":"Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber","volume":"124","author":"Horak","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib123","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaci.2014.12.1911","article-title":"Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber","volume":"135","author":"Nolte","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib124","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clinthera.2019.02.008","article-title":"The importance of tablet formulation on allergen release kinetics and efficiency: comparison of freeze-dried and compressed grass pollen sublingual allergy immunotherapy tablet formulations","volume":"41","author":"Lund","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2020.04.071_bib125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000479693","article-title":"Bioavailability of house dust mite allergens in sublingual allergy tablets is highly dependent on the formulation","volume":"174","author":"Ohashi-Doi","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib126","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.anai.2019.03.023","article-title":"Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey","volume":"122","author":"Sivam","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib127","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jaci.2013.10.041","article-title":"Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis","volume":"133","author":"Creticos","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib128","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.anai.2016.12.009","article-title":"Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update","volume":"118","author":"Greenhawt","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaci.2010.08.030","article-title":"Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study","volume":"126","author":"Marogna","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaci.2010.10.025","article-title":"Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy","volume":"127","author":"Tabar","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib131","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/lary.23935","article-title":"Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"123","author":"Wang","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2020.04.071_bib132","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1398-9995.2007.01416.x","article-title":"Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy","volume":"62","author":"Calderon","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib133","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/all.13420","article-title":"EAACI guidelines on allergen immunotherapy: executive statement","volume":"73","author":"Muraro","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/MCP.0000000000000227","article-title":"Update on immunotherapy for the treatment of asthma","volume":"22","author":"Canonica","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2020.04.071_bib135","first-page":"S1","article-title":"Allergy diagnostic testing: an updated practice parameter","volume":"100","author":"Bernstein","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib136","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/0091-6749(92)90382-C","article-title":"The histamine content of allergen extracts","volume":"89","author":"Williams","year":"1992","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib137","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0091-6749(99)70171-5","article-title":"Specific IgE to cross-reactive carbohydrate determinants strongly affect the in\u00a0vitro diagnosis of allergic diseases","volume":"103","author":"Mari","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib138","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2045-7022-1-15","article-title":"Sensitization to cereals and peanut evidenced by skin prick test and specific IgE in food-tolerant, grass pollen allergic patients","volume":"1","author":"Martens","year":"2011","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib139","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/all.13416","article-title":"EAACI position paper on the standardization of nasal allergen challenges","volume":"73","author":"Auge","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 23","key":"10.1016\/j.jaip.2020.04.071_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/pai.12563","article-title":"EAACI molecular allergology user\u2019s guide","volume":"27","author":"Matricardi","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib141","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1939-4551-6-17","article-title":"WAO - ARIA - GA(2) LEN consensus document on molecular-based allergy diagnostics","volume":"6","author":"Canonica","year":"2013","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2020.04.071_bib142","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/pai.12991","article-title":"Detection of genuine grass pollen sensitization in children by skin testing with a recombinant grass pollen hybrid","volume":"30","author":"Douladiris","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib143","first-page":"303","article-title":"Preparing and mixing allergen vaccines for subcutaneous immunotherapy","volume":"21","author":"Nelson","year":"2008","journal-title":"Clin Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib144","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2019.01.032","article-title":"Mind the gaps: clinical trial concepts to address unanswered questions in aeroallergen immunotherapy-An NIAID\/AHRQ Workshop","volume":"143","author":"Wheatley","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaip.2015.11.004","article-title":"Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated","volume":"4","author":"Maloney","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib146","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.alit.2019.03.005","article-title":"Dual sublingual immunotherapy with Japanese cedar pollen droplets and house dust mite tablets","volume":"68","author":"Matsuoka","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.04.071_bib147","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3950\/jibiinkoka.122.126","article-title":"[Safety of sequential sublingual immunotherapy with Japanese cedar pollen and mite allergens]","volume":"122","author":"Yuta","year":"2019","journal-title":"Nippon Jibiinkoka Gakkai Kaiho (Tokyo)"},{"key":"10.1016\/j.jaip.2020.04.071_bib148","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.alit.2019.07.007","article-title":"Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet","volume":"69","author":"Gotoh","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2020.04.071_bib149","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/all.12074","article-title":"Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects","volume":"68","author":"Nelson","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib150","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2013.03.013","article-title":"Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy","volume":"132","author":"Kiel","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib151","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/ACI.0b013e328332b8df","article-title":"Evidence of adherence to allergen-specific immunotherapy","volume":"9","author":"Senna","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib152","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2014.01.010","article-title":"Allergy immunotherapy adherence and delivery route: location does not matter","volume":"2","author":"Cox","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.04.071_bib153","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.jaci.2017.12.999","article-title":"Comparison of allergy immunotherapy medication persistence with a sublingual immunotherapy tablet versus subcutaneous immunotherapy in Germany","volume":"141","author":"Allam","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib154","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.anai.2015.06.018","article-title":"Non-adherence to subcutaneous allergen immunotherapy: inadequate health insurance coverage is the leading cause","volume":"115","author":"Vaswani","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib155","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/all.12198","article-title":"Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach","volume":"68","author":"Savi","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib156","first-page":"141","article-title":"Adherence issues related to sublingual immunotherapy as perceived by allergists","volume":"4","author":"Scurati","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaip.2020.04.071_bib157","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2019.03.009","article-title":"Understanding patient experiences with allergen immunotherapy: \u201cliving with allergies study\u201d","volume":"123","author":"Stone","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2020.04.071_bib158","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1398-9995.2010.02347.x","article-title":"Importance of patient's education in favouring compliance with sublingual immunotherapy","volume":"65","author":"Incorvaia","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.04.071_bib159","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2500\/aap.2011.32.3453","article-title":"Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen","volume":"32","author":"DuBuske","year":"2011","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2020.04.071_bib160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.anai.2018.10.005","article-title":"Improved patient adherence to subcutaneous allergen immunotherapy using a modified rush immunotherapy protocol","volume":"122","author":"Teachout","year":"2019","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820304797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820304797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:27:21Z","timestamp":1761974841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820304797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":157,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2213219820304797"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.04.071","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Practice of Allergen Immunotherapy for Allergic Rhinoconjunctivitis and Asthma: An Expert Panel Report","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.04.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}